[.
]Action/Kinetics:
Has both beta-1 and beta-2 receptor blocking activity. It has no membrane-stabilizing activity but does have moderate intrinsic sympathomimetic effects. Low lipid solubility. t1/2: 6 hr. Duration, ophthalmic use: 12 hr. Approximately 50%-70% excreted unchanged in the urine.
Uses:
PO. Hypertension. Investigational: Reduce frequency of anginal attacks. Ophthalmic. Alone or with other drugs to lower IOP in chronic open-angle glaucoma and intraocular hypertension.
Contraindications:
Severe, persistent bradycardia. Bronchial asthma or bronchospasm, including severe COPD.
Special Concerns:
Dosage not established in children.
Additional Side Effects:
Ophthalmic use. Transient irritation, burning, tearing, conjunctival hyperemia, edema, blurred or cloudy vision, photophobia, decreased night vision, ptosis, blepharoconjunctivitis, abnormal corneal staining, corneal sensitivity.
How Supplied:
Ophthalmic solution: 1%; Tablet: 2.5 mg, 5 mg
Dosage
•Tablets
Hypertension.
Initial: 2.5 mg once daily either alone or with a diuretic. If response is inadequate, the dose may be increased gradually to 5 mg and then 10 mg/day as a single dose. Maintenance: 2.5-5 mg once daily. Doses greater than 10 mg/day are not likely to increase the beneficial effect and may decrease the response. Increase the dosage interval in clients with renal impairment.
Reduce frequency of anginal attacks.
10 mg/day.
•Ophthalmic Solution
Usual: 1 gtt in affected eye b.i.d. If the response is unsatisfactory, concomitant therapy may be initiated.
Discuss prescriptions and health topics in the new 